Literature DB >> 20953258

Correspondence (letter to the editor): Notorious weaknesses.

Jürgen Maares.   

Abstract

Mesh：

Year:  2010        PMID： 20953258      PMCID： PMC2954520          DOI： 10.3238/arztebl.2010.0670a

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  2 in total

1.  The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.

Authors:  Gisela Schott; Henry Pachl; Ulrich Limbach; Ursula Gundert-Remy; Wolf-Dieter Ludwig; Klaus Lieb
Journal:  Dtsch Arztebl Int       Date:  2010-04-23       Impact factor: 5.594

Review 2.  The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.

Authors:  Gisela Schott; Henry Pachl; Ulrich Limbach; Ursula Gundert-Remy; Klaus Lieb; Wolf-Dieter Ludwig
Journal:  Dtsch Arztebl Int       Date:  2010-04-30       Impact factor: 5.594
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.